Lipid abnormalities in end stage renal disease.

fibrate, hypercholesterolemia, hypertriglyceridemia, 3-hydroxy-3-methylglutaryl coenzyme A reductase extent the putative risk factors listed above interact with lipid abnormalities in patients with uraemia. inhibitor Finally, no data are available to address the important issue of whether risk factor modification will improve the ESRD patient survival.

[1]  B. Kasiske,et al.  Cardiovascular disease after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[2]  A. Więcek,et al.  Organ and Metabolic Complications: Lipids/Atherosclerosis , 1996 .

[3]  D. O'Neal,et al.  Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  C. Wanner,et al.  Clinical utility of antilipidemic therapies in chronic renal allograft failure. , 1995, Kidney international. Supplement.

[5]  G. Siest,et al.  Apolipoprotein E: an important gene and protein to follow in laboratory medicine. , 1995, Clinical chemistry.

[6]  W. Zidek,et al.  Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. , 1995, Journal of the American Society of Nephrology : JASN.

[7]  T. Louis,et al.  Lipid-lowering therapy in patients with renal disease. , 1995, Kidney international.

[8]  B. Kasiske,et al.  Clinical correlation between renal allograft failure and hyperlipidemia. , 1995, Kidney international. Supplement.

[9]  W. Keane.  Lipids and the kidney. , 1994, Kidney international.

[10]  F. Kronenberg,et al.  Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  R. Omoto,et al.  Lipid and lipoprotein(a) in renal transplant recipients. , 1994, Transplantation proceedings.

[12]  G. Bellomo,et al.  Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? , 1994, Kidney international.

[13]  J. Coresh,et al.  Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. , 1993, Journal of lipid research.

[14]  D. de Zeeuw,et al.  Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. , 1993, Kidney international.

[15]  K. Lai,et al.  Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis. , 1993, Australian and New Zealand journal of medicine.

[16]  O. Samuelsson,et al.  Lipoprotein metabolism and renal failure. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  K. Lai,et al.  Lovastatin Treatment of Dyslipoproteinemia in Patients on Continuous Ambulatory Peritoneal Dialysis , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[18]  A. Evangeliou,et al.  Evaluation of Carnitine Levels According to the Peritoneal Equilibration Test in Patients on Continuous Ambulatory Peritoneal Dialysis , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[19]  F. Scanferla,et al.  Effect of Hypertriglyceridemia Correction by Omega-3 Fatty Acids on Peritoneal Transport in Continuous Ambulatory Peritoneal Dialysis Patients , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[20]  Jacobson Rh,et al.  Lipid-lowering effects of lovastatin in CAPD patients. , 1993 .

[21]  V. Sparacino,et al.  Lipoprotein (a) levels in end-stage renal failure and renal transplantation. , 1993, Nephron.

[22]  G. Bellomo,et al.  Low-density lipoprotein oxidation and antioxidized LDL antibodies in peritoneal dialysis patients. , 1993, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[23]  M. Elisaf,et al.  Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. , 1993, Scandinavian journal of urology and nephrology.

[24]  J. Belch,et al.  Lipid Perxidtion and Antioxidants in Continuous Ambulatory Dialysis Patients , 1992, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[25]  T. Oka,et al.  Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease. , 1992, Nephron.

[26]  J. Fruchart,et al.  Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. Cannon,et al.  Cardiovascular complications in renal failure. , 1991, Journal of the American Society of Nephrology : JASN.

[28]  P. Parfrey,et al.  The natural history of myocardial disease in dialysis patients. , 1991, Journal of the American Society of Nephrology : JASN.

[29]  R. Rebourcet,et al.  Abnormal concentrations of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients. , 1991, Clinical chemistry.

[30]  J. Fruchart,et al.  Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.

[31]  Y. Bar-Khayim,et al.  Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. , 1990, Kidney international.

[32]  B. Kasiske,et al.  Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease , 1990 .

[33]  R. Havel,et al.  Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism , 1988, Hepatology.

[34]  T. Hutchinson,et al.  Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. , 1987, Atherosclerosis.

[35]  A. Pasternack,et al.  Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. , 1987, Clinical nephrology.

[36]  B. Lindholm,et al.  Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. , 2009, Acta medica Scandinavica.

[37]  R. Carney,et al.  Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. , 1986, Nephron.

[38]  G. Utermann,et al.  Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[39]  O. Nyquist,et al.  Acute myocardial infarction in renal transplant recipients: incidence and prognosis. , 1984, European heart journal.

[40]  D. Oreopoulos,et al.  The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. , 1982, Atherosclerosis.

[41]  D. B. Zilversmit,et al.  Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. , 1982, Journal of lipid research.

[42]  Z. Varghese,et al.  Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal. , 1982, Clinical nephrology.

[43]  Z. Varghese,et al.  Plasma lecithin-cholesterol acyltransferase activities in uraemic patients. , 1982, Clinica chimica acta; international journal of clinical chemistry.

[44]  Z. Varghese,et al.  Lipid abnormalities in uremia, dialysis, and transplantation. , 1981, Kidney international.

[45]  G. Reaven,et al.  Response of plasma triglycerides to dietary change in patients on hemodialysis. , 1978, Kidney international.